Displaying drugs 12951 - 12975 of 14395 in total
Murlentamab
Investigational
Lerapolturev
Investigational
ALT-P7
Investigational
G100
Investigational
ST-36
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
Investigational
LV305
LV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with G305.
Investigational
Leuvectin
Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE).
Investigational
KTH-222
Investigational
Belzupacap Sarotalocan
Investigational
ADXS-31164
Investigational
Eltrapuldencel-T
Investigational
Inalimarev
Investigational
IMGN779
Investigational
ICG-140
Investigational
MORAb-066
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
OBI-999
Investigational
STM-217
Investigational
Autologous DNP-conjugated tumour vaccine
Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.
Investigational
RR001
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
Bersanlimab
Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).
Investigational
WTx-Bortezomib
Experimental
Displaying drugs 12951 - 12975 of 14395 in total